Literature DB >> 30426302

Overexpression of CTRP9 attenuates the development of atherosclerosis in apolipoprotein E-deficient mice.

Chengmin Huang1,2,3, Peng Zhang1,2,4, Tingting Li1,2,5, Jun Li1,2, Tianjiao Liu2, Anju Zuo2,5, Jiying Chen1,2,5, Yuan Guo6,7,8.   

Abstract

This study was aimed to explore the role of C1q/TNF-related protein 9 (CTRP9) on atherosclerotic lesion formation. A recombinant lentiviral vector carrying mouse CTRP9 (Lv-CTRP9) was injected intravenously into apolipoprotein E knockout (ApoE-/-) mice given a high-fat diet (HFD). CTRP9 overexpression substantially attenuated atherosclerotic lesion size of mice. The accumulation of macrophages and smooth muscle cells (SMCs) was significantly decreased in atherosclerotic regions with CTRP9 overexpression by immunohistochemical analysis. In addition, CTRP9 downregulated the expressions of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α), two main proinflammatory cytokines in atherosclerosis. Furthermore, the autophagy level remarkably increased which was presented by microtubule-associated protein light chain 3B (LC3B) conversion and sequestosome 1 (SQSTM1/p62) degradation. Further study showed that CTRP9 increased adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and decreased mammalian target of rapamycin (mTOR) phosphorylation in vivo. These observations reveal that CTRP9 exerts a protecting role in early atherosclerotic lesions and its anti-atherosclerotic effect is associated with autophagy induction through AMPK/mTOR signaling pathway.

Entities:  

Keywords:  AMPK; Atherosclerosis; Autophagy; CTRP9; mTOR

Mesh:

Substances:

Year:  2018        PMID: 30426302     DOI: 10.1007/s11010-018-3473-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  45 in total

1.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.

Authors:  Y Kabeya; N Mizushima; T Ueno; A Yamamoto; T Kirisako; T Noda; E Kominami; Y Ohsumi; T Yoshimori
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

4.  Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis.

Authors:  Rajbabu Pakala; Eugenio Stabile; Gil Jin Jang; Leonardo Clavijo; Ron Waksman
Journal:  J Cardiovasc Pharmacol       Date:  2005-10       Impact factor: 3.105

Review 5.  Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.

Authors:  Guido Stoll; Martin Bendszus
Journal:  Stroke       Date:  2006-06-01       Impact factor: 7.914

Review 6.  Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress.

Authors:  Karen S Meir; Eran Leitersdorf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-15       Impact factor: 8.311

Review 7.  Mouse models of experimental atherosclerosis.

Authors:  J Jawień; P Nastałek; R Korbut
Journal:  J Physiol Pharmacol       Date:  2004-09       Impact factor: 3.011

8.  Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin.

Authors:  G William Wong; Sarah A Krawczyk; Claire Kitidis-Mitrokostas; Guangtao Ge; Eric Spooner; Christopher Hug; Ruth Gimeno; Harvey F Lodish
Journal:  FASEB J       Date:  2008-09-11       Impact factor: 5.191

Review 9.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits.

Authors:  Roberta Baetta; Agnese Granata; Monica Canavesi; Nicola Ferri; Lorenzo Arnaboldi; Stefano Bellosta; Pascal Pfister; Alberto Corsini
Journal:  J Pharmacol Exp Ther       Date:  2008-11-20       Impact factor: 4.030

View more
  6 in total

Review 1.  Adipokines, adiposity, and atherosclerosis.

Authors:  Longhua Liu; Zunhan Shi; Xiaohui Ji; Wenqian Zhang; Jinwen Luan; Tarik Zahr; Li Qiang
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

2.  CTRP9 mitigates vascular endothelial cell injury in patients with hypertensive heart disease by inhibiting PI3K/Akt/mTOR axis.

Authors:  Lingyun Pan; Xiaocui Sun; Haixia Che; Mingzhe Li
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 3.  Targeting non-coding RNAs in unstable atherosclerotic plaques: Mechanism, regulation, possibilities, and limitations.

Authors:  Xiaoxin Li; Yanyan Yang; Zhibin Wang; Shaoyan Jiang; Yuanyuan Meng; Xiaoxia Song; Liang Zhao; Lu Zou; Min Li; Tao Yu
Journal:  Int J Biol Sci       Date:  2021-08-03       Impact factor: 6.580

4.  C1q/TNF-Related Protein 9 Attenuates Atherosclerosis by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the AMPKα/KLF4 Signaling Pathway.

Authors:  Gang Wang; Baihe Han; Ruoxi Zhang; Qi Liu; Xuedong Wang; Xingtao Huang; Dandan Liu; Weishen Qiao; Mengyue Yang; Xing Luo; Jingbo Hou; Bo Yu
Journal:  Front Pharmacol       Date:  2021-10-22       Impact factor: 5.810

Review 5.  C1q/Tumor Necrosis Factor-Related Protein 9: Basics and Therapeutic Potentials.

Authors:  Hua Guan; Yanli Wang; Xiangyu Li; Aoqi Xiang; Fengwei Guo; Jianglin Fan; Qi Yu
Journal:  Front Physiol       Date:  2022-03-18       Impact factor: 4.566

6.  Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway.

Authors:  Jin Zou; Can Xu; Zhen-Wang Zhao; Shan-Hui Yin; Gang Wang
Journal:  J Transl Med       Date:  2022-07-28       Impact factor: 8.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.